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The gene has been proposed as an attractive unit of analysis for association studies, but a simple yet valid, powerful, and sufficiently fast
method of evaluating the statistical significance of all genes in large, genome-wide datasets has been lacking. Here we propose the use of
an extended Simes test that integrates functional information and association evidence to combine the p values of the single nucleotide
polymorphisms within a gene to obtain an overall p value for the association of the entire gene. Our computer simulations demonstrate
that this test is more powerful than the SNP-based test, offers effective control of the type 1 error rate regardless of gene size and linkage-
disequilibrium pattern among markers, and does not need permutation or simulation to evaluate empirical significance. Its statistical
power in simulated data is at least comparable, and often superior, to that of several alternative gene-based tests. When applied to
real genome-wide association study (GWAS) datasets on Crohn disease, the test detected more significant genes than SNP-based tests
and alternative gene-based tests. The proposed test, implemented in an open-source package, has the potential to identify additional
novel disease-susceptibility genes for complex diseases from large GWAS datasets.Introduction
Genome-wide association studies (GWASs) are being
used for identification of susceptibility loci for complex
diseases.1 These studies typically use the single nucleotide
polymorphism (SNP) as the basic unit of analysis, which is
a convenient strategy and has led to the discovery of many
important genetic loci for human diseases.2 However, the
statistically significant variants detected so far explain
only a modest proportion of the total variance in liability
to disease, and inadequate statistical power is likely to
have contributed to the failure to detect true effects.3,4
The problem of statistical power is exacerbated by the
necessity of adopting stringent p value thresholds for
significance (typically 5 3 108) in order to control false-
positive association from the large number of SNPs tested.
In addition, many significant SNPs are likely to represent
surrogate markers in linkage disequilibrium (LD) with the
variants causing diseases, and differences in LD patterns
across populations can lead to nonreplication of the
same SNP in another population but significant associa-
tion for some other surrogate SNPs.5
Shifting from SNP-based association analysis to gene-
based analysis is one possible way to improve the power
of GWASs. In a gene-based analysis, one jointly analyzes
all variants within a putative gene to obtain a single p value
representing the significance of association of the entire
gene. Analysis using the gene as the basic unit has several
attractive features. First, the gene is the functional unit of
the human genome. Unlike genetic variants that have
different allele frequencies, LD structure, and heteroge-
neity across diverse human populations, the gene itself is
highly consistent across populations.6 Gene-based analysis1Department of Psychiatry and State Key Laboratory for Cognitive and Brain Sc
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ates difficulties in replication. Second, gene-based analysis
reduces the multiple-testing burden substantially; it
requires correction for approximately 20,000–30,000
genes rather than potentially millions of SNPs. Finally,
with the gene as the unit of analysis, extension of the find-
ings to further functional analyses, such as protein-protein
interactions (PPIs) and biological pathways, is more
straightforward. The integration of association evidence
and functional informationmight facilitate the unraveling
of the pathogenic mechanisms of complex diseases.
A number of gene-based association tests have been
proposed. Linear regression (for quantitative traits) and
logistic regression (for binary traits) are straightforward
methods of evaluating the overall association between
a gene and a trait. In these tests, all the SNPs or haplotypes
in the gene are entered as predictor variables simulta-
neously, except for redundant SNPs,whose inclusionwould
result in collinearity.6However, a simple regression analysis
might suffer from low statistical power if many SNPs or
haplotypes are included, resulting in a test with many
degrees. Many methods reduce the dimensionality of the
test by compressing the information in the multiple corre-
lated SNPs, for example by Fourier transformation,7 prin-
cipal-components analysis,8,9 the use of fixed SNP weights
based on the LD pattern across the gene,10 and cluster anal-
ysis.11 All these regression-basedmethods require the avail-
ability of the raw, individual phenotype and genotype data.
Methods involving the combination of the SNP-based
test statistics or p values have also been proposed. The
largest test statistic from all the SNP-based tests in a gene
has been proposed as a gene-based test statistic.12 However,
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correlated with the number of SNPs in the gene, and
although adjustment for gene size by a permutation proce-
dure is possible, this is time consuming for large datasets.12
Another possible method is to combine the p values of the
SNPs in a gene by Fisher’s combination test.13 However,
this method assumes that the constituent p values should
be based on independent tests, which is unlikely to be true
for SNPs in the same gene. Violation of this assumption is
likely to inflate the type I error rate, unless use of a permu-
tation procedure provides empirical statistical significance.
A variant of the Fisher’s method is the truncated-product
p value method,14 which was originally developed to
deal with ‘‘publication bias’’ in meta-analysis.15 However,
like the Fisher’s combinationmethod, this test is also sensi-
tive to LD among the SNPs in a gene and therefore requires
a permutation procedure if an empirical p value is to be ob-
tained. Instead of permutation, which requires raw geno-
type data, a recent variation of the Fisher’s combination
test uses a simulation approach based on normal variables
with correlations that are assigned values according to the
LD structure between SNPs.16 The p values of this method
are highly correlated with those obtained from a permuta-
tion procedure. The simulation method, although faster
than permutation, is still computationally intensive
when applied to genome-wide datasets.
A separate issue for the design of gene-based tests is the
possibility of improving the power of the test by imposing
weights on the SNPs according to prior information on
their likely relative importance. The idea of p value weights
was introduced in the context of a sequential step-down
test for maintaining the family-wise type 1 error rate17
and was subsequently incorporated into a false-discovery
rate (FDR) procedure.18 A procedure for assigning prior p
value weights based on a mixture model for p values has
been suggested.19 Indeed, given the observed p values, it
is possible to optimize the choice of p value weights to
be applied to tests grouped by prior information.20
However, because the observed dataset might contain
limited information, it might be desirable to also make
use of established functional information and prior data
in the assignment of p value weights.
In this paper, we propose a rapid gene-based association
test that uses extended Simes procedure (GATES) to assess
the gene-level statistical association significance that
can efficiently handle results based on millions of SNPs
(possibly from imputation and meta-analysis) in the later
stages of GWASs and next-generation sequencing studies.
This test can rapidly combine the p values of SNPs within
a gene, without relying on raw, individual phenotype and
genotype data, to produce valid gene-based p values. This
gene-based test can also incorporate functional informa-
tion on SNPs by the use of prior weights to increase statis-
tical power. After introducing the test, we present a series
of computer simulations that are useful in investigating
the test’s type 1 error rate, and we compare the test’s statis-
tical power with that of alternative gene-based tests. To
assess its performance in real datasets, we applied the284 The American Journal of Human Genetics 88, 283–293, March 1method to GWAS data on Crohn disease (CD [MIM
266600]).Material and Methods
Construction of Gene-Based-Association p Value
We assume that a test of association between the disease and each
of the available SNPs within a gene has been carried out and that
the resulting p values and pair-wise correlation coefficients r for all
the SNPs are available. The proposed method, GATES, a modifica-
tion of the Simes test, combines these available p values to give
a gene-based p value. Let p(1), ., p(m) be the ascending p values
ofm SNPs within a gene. We propose combining them SNP-based
p values to obtain an overall p value for the gene as follows:
PG ¼ Min

mepðjÞ
meðjÞ

;
where me is the effective number of independent p values among
the m SNPs and me(j) is the effective number of independent p
values among the top j SNPs. The null hypothesis of this gene-
based test is that no SNP within the gene is associated with the
disease, whereas the alternative is that at least one SNP in the
gene is associated with the disease.
In the test proposed above, we used a measure that is more
robust than those currently available21–24 (unpublished data) to
obtain me. The value of me is estimated to be equal to
M PM
i¼1
½Iðli > 1Þðli  1Þ li > 0 , where I(x) is an indicator function
and li is the i
th eigenvalue of the p value correlation coefficient
matrix ½ri;j of SNP-based statistic tests. The negative eigenvalues
are set as zero and ignored. Negative eigenvalues should only arise
in the presence of missing data, and they are usually relatively few
in number and close to zero.21 When the SNPs are independent,
the eigenvalues are all 1, so that me is equal to the number of
SNPs. When all the SNPs are in complete LD, the first eigenvalue
is equal to the number of SNPs and the rest are 0, so that me ¼ 1.
For intermediate situations, we have performed simulation and
permutation studies (see below) to show that the formula also
provides an appropriate effective number of SNP p values and that
PG will thus have an approximate uniform (0,1) distribution.
18,25
For a simple case-control study, the pair-wise SNP p value corre-
lation coefficient r is expected to be mainly determined by the
pair-wise LD between the two corresponding SNPs, as measured
by the allelic correlation coefficient r, although it could also be
influenced by the allele frequencies of the two SNPs and the
numbers of cases and controls in the study. We explored the rela-
tionship r and r, for different allele frequencies and sample sizes,
empirically by simulation. Genotype data of two biallelic SNPs
were simulated for 1,500 cases and 1,500 controls, for a particular
set of values of r and allele frequencies, under Hardy-Weinberg
equilibrium. We then performed an allelic association test for
each of the two SNP to obtain two p values. Repeating this proce-
dure 100,000 times resulted in 100,000 sets of p values, from
which the correlation coefficient of the p values of the two SNPs,r,
was calculated.We increased the allele frequencies and r in steps of
0.05 from their minimum to their maximum values to generate
a series of data points. It turned out that the p value correlation
coefficient r could be accurately approximated by a sixth-order
polynomial function of the pair-wise allelic correlation coefficient
r (coefficient of determination R2 ¼ 0.9986), regardless of allele1, 2011
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Figure 1. The Relationship between LD r and Correlation Coef-
ficient of p Values by Curve Fittingfrequencies (see Figure 1). Repeated simulations using samples of
different sizes and quantitative traits (analyzed by linear regres-
sion) also yielded the same polynomial approximation.
The gene-based test can be further extended to incorporate
differential SNP weights as follows:
PG ¼ Min
0
BBB@
mepðjÞ
Pj
k¼1
wðkÞ
1
CCCA;
wherew(1),.,w(m) are non-negative and sum tome. These weights
are calculated from prior weights r(1),., r(m), set according to the
relative functional importance of the SNP to non-negative values
but otherwise unconstrained. The procedure takes in turn the
sorted SNPs, according w(i) ¼ c(me(i)  me(i-1))r(i), where me(0) ¼
0 and c is defined such that the weights sum to me:
c ¼ mePm
i¼1

meðiÞ meði1Þ

rðiÞ
The use of weights is expected to increase statistical power if SNPs
with higher weights are more likely to be associated with disease
than SNPs with lower weights. In the absence of information,
equal weights can be used.Alternative Gene-Based Tests
We performed simulation studies to compare the type 1 error rate
and statistical power of GATES with those of the following alterna-
tive gene-based tests:
d Logistic regression. Each SNP is entered as an explanatory
variable, coded as 0, 1, or 2 for the number of copies of the
minor allele in the genotype, and case-control status is coded
as the response variable. A gene-based p value is provided by
the likelihood ratio test comparing the full model with all
available SNPs and the null model without any SNP.
d Fisher combination test. The gene-based test statistic is given
by T ¼ 2Pm
j¼1
lnpðjÞ, which has a chi-square distribution with
2m degrees of freedom under the null hypothesis when the
m tests are independent.26 The test is expected to be liberalThe Amerifor positively correlated tests, such that a permutation proce-
dure is needed if a valid p value is to be obtained.13
d Original Simes test. The gene-based p value is PS ¼
minðmpðjÞ=jÞ. For independent tests, PS is uniform (0,1) under
the null hypothesis. For positively correlated tests, PS is
expected to be conservative.
d Aversatilegene-based test for genome-wideassociation studies
(VEGAS) proposed recently by Liu et al. (2010).16 The test
allows the SNP-based chi-square test statistics within a gene
to be combined in a flexible manner to give a gene-based test
statistic (e.g., it can take the sum of all the statistics, or the
sumof the several top statistics, or simply the largest statistic).
An empirical null distribution for this gene-based test statistic
is obtained through a simulation of multivariate standard
normal random vectors with correlations equal to those
between the SNPs in the gene; the component variables are
squared to give correlated chi-square random variables, and
then appropriate variables are summed as dictated by how
the gene-based test statisticwas calculated. In our simulations,
we calculated two versions of the test, one basedon the sumof
all the SNP-based chi-square statistics in the gene (VEGAS-
Sum) and one based on just the largest statistic (VEGAS-Max).
Note that only logistic regression requires the raw phenotype
and genotype data, whereas the other tests require only the SNP-
based p values. However, a permutation procedure, which is neces-
sary to ensure the correct type 1 error rates for the Fisher and orig-
inal Simes tests when the SNPs are correlated, also requires the raw
data. The VEGAS method does not require raw data but instead
requires only the correlation matrix of the SNPs.Simulation Studies of Type 1 Error Rate
and Statistical Power
The simulation involved the generation of genotype data on 30
SNPs, which were all biallelic and under Hardy-Weinberg equilib-
rium.We considered three different scenarios in terms of LD struc-
ture: (1) the SNPs are situated in six strong LD blocks (see Table S1),
(2) the SNPs are situated in six moderate LD blocks (see Table S2),
or (3) the SNPs are in linkage equilibrium. Given the LD pattern
and the allele frequencies of the 30 SNPs, we used a program based
on the HapSim algorithm27 to generate genotype data. We then
considered three different scenarios in terms of gene size: (1)
a three-SNP gene containing the first three SNPs, (2) a ten-SNP
gene containing the first ten SNPs, and (3) a 30-SNP gene contain-
ing all 30 SNPs. Finally, we considered three scenarios in terms of
disease model: (1) a null model where no SNP has any effect on
disease risk, (2) an additivemodel where one SNP in each LD block
has a minor allele that increases the risk ratio additively by 0.14,
and (3) a multiplicative model where one SNP in each LD block
has a minor allele that increases the risk ratio multiplicatively by
a factor of 1.14 (see Tables S1 and S2).28 Because three-SNP, ten-
SNP, and 30-SNP genes contain one, two, and six LD blocks,
respectively, the number of susceptibility SNPs they contain are
correspondingly one, two, and six. The baseline risk correspond-
ing to the absence of any risk-increasing alleles is calculated
from the allele frequencies and risk ratios of the susceptibility
SNPs and gives a population disease prevalence of 0.1. For each
combination of scenarios, a population of 1,000,000 individuals
was generated. A random sample of 1500 cases and 1500 controls
was drawn, without replacement, from the population and sub-
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error rates and statistical power estimates under the different
scenarios were obtained from the proportion of simulated data-
sets, out of 1,000 simulated populations, that resulted in signifi-
cant p values (set at 0.05).
Impact of Weighting on Type 1 Error Rates
and Statistical Power
To evaluate the impact of weighting the SNPs in the construction
of the gene-based test, we assigned some SNP with a high weight
(wi > 1) and the others with a low weight (0 < wi < 1) in simulated
data generated as described above. We considered two scenarios of
weight assignment: (1) the SNPs assigned to have the high weight
are the true susceptibility SNPs, whereas the SNPs assigned to have
the lowweight have no direct causal effect, and (2) the assignment
of weight is random. Although the first scenario is expected to
increase statistical power, the latter scenario is expected to have
no effect or to result in reduced statistical power. Although
random assignment is not the worst possible scenario, it might
be the worst that is likely to occur in real data analyses. We also
varied the ratio of high to low weights from 1 to 16 to see the
impact on type 1 error rates and statistical power.
Genome-wide Type 1 Error Rates under Realistic
LD Patterns
The above evaluation of type 1 error rates in simulation was based
on arbitrary LD structure and might not represent realistic exam-
ples of the actual LD structure of genes in real populations. In
order to assess the genome-wide type 1 error rates under realistic
situations, we calculated the various gene-based test statistics for
genotype data from a real GWAS, where the phenotypes were reas-
signed at random. The real GWAS data used were on a sample of
2514 Chinese subjects typed by the Illumina Human610-Quad
BeadChip from projects in Hong Kong with Institutional Review
Board approval. After standard quality-control procedures,
473,931 SNPs were left for analysis; among these, 209,784 SNPs
were in 23,672 genes. SNP-based association analysis was carried
out with a genotypic association test in Plink.29 Two LD datasets
from different sources were prepared: the pair-wise r-squares esti-
mated through Plink29 from the genotype data of the actual case-
control sampleand the r-squares fromthe latestHapMapLDdataset
(CHBpanel) released onApril 19, 2009.WeusedGATES to combine
SNP-level p values to obtain gene-basedpvalues.We assessed type1
error rates for the gene-based tests by examining the proportion of
genes for which the gene-based p value is lower than various
threshold values (0.05., 0.01, 0.001, 0.0001). In addition, we used
a quantile-quantile (Q-Q) plot to compare the overall distribution
of the gene-based p values to a uniform (0,1) distribution.
Application to GWASs
To further evaluate the performance of GATES under realistic situ-
ations, we used it to reanalyze the data from a published meta-
analysis of three CD GWASs with a total of 3,230 cases and
4,829 controls.30 We used the r-square values from the HapMap
CEU sample to adjust for marker dependency. Prior to applying
GATES, we subjected the SNP-based p values to genomic control
correction31 to avoid inflated significance levels. SNPs were map-
ped onto genes according to the gene coordinate information
from NCBI. SNPs within 5 kilobase pairs of each gene were also as-
signed into the gene. In the very rare case where a SNP was in the
overlapping region of two genes, the SNP was assigned into both
genes.We compared the results of the SNP-based tests, the original286 The American Journal of Human Genetics 88, 283–293, March 1Simes test and GATES, in terms of the number of significant hits
after Bonferroni correction.Results
Simulation Studies of Type 1 Error Rate
and Statistical Power
The empirical type 1 error rates and statistical powers of
GATES and the five alternative methods at a nominal
type 1 error rate (a) of 0.05 are given in Table 1. When
the markers within a gene are independent, the empirical
type 1 error rates of all tests are approximately 0.05. For
dependent markers, however, the Fisher combination test
is a liberal test with an inflated type 1 error rate. In
contrast, the original Simes test becomes conservative for
a gene with multiple SNPs in strong LD. The type 1 error
rates of the other five tests (including the one we propose)
are all correct regardless of the marker dependency.
The statistical powers of the tests are affected by the
number of disease-susceptibility loci (DSL) and the marker
dependency.When themarkers are independent and there
are only 1 or 2 susceptibility loci (i.e., in the case of the
three-SNP or ten-SNP gene), all the tests have approxi-
mately equal power to identify the susceptibility genes.
When a gene has 30 SNPs and six susceptibility loci, the
most powerful tests are those that combine the evidence
from all the SNPs in an additive manner, i.e., logistic
regression, Fisher’s combination, and VEGAS-Sum (see
Table 1). GATES has power comparable to that of the
VEGAS-Sum test in the three-SNP and ten-SNP scenarios,
but it is slightly less powerful for a gene with 30 SNPs
and six susceptibility loci. It is more powerful than logistic
regression when the markers are in strong LD, and it is
similar or superior in power to the original Simes test or
the VEGAS-Max test in all situations.
The powers of the Fisher combination test with permuta-
tion, the original Simes test with permutation, and GATES
are shown in Table 2. In general, all three tests have very
similar powers, with a few exceptions. One of these situa-
tions is when there are six susceptibility loci (among 30
SNPs), in which case the Fisher combination test is more
powerful than the other two tests. Another is when there
is only one susceptibility locus among a large number
(i.e., 10) of independent SNPs, in which case the Fisher
combination test is less powerful than the other two tests.Impact of Weighting on Type 1 Error Rates
and Statistical Power
The use of weights does not lead to an inflated type 1 error
rate for GATES (see Figure 2). However, weight setting can
have substantial effects on statistical power. When the
SNPs are independent or in moderate LD, the assignment
of relatively high weights to the true susceptibility SNPs
can substantially increase the power of the gene-based
test (see Figure 2). The bigger the difference between the
high and the low weights, the greater the power gain.1, 2011
Table 1. Empirical Type 1 Errors and Power of Alternative Approaches (in percentage)
#SNP (#DSL) Logistic Regression Fisher VEGAS –Sum Original Simes VEGAS Max GATES
LE
Error Rate (no disease) 3(0) 4.66 4.67 4.70 4.61 4.62 4.61
10(0) 5.10 5.00 5.04 5.06 5.07 5.06
30(0) 5.26 4.96 4.97 4.97 5.04 4.97
Power (additive model) 3(1) 43.71 41.79 42.67 45.28 45.22 45.28
10(2) 56.88 53.32 54.56 54.76 54.00 54.76
30(6) 65.32 61.5 63.28 47.18 45.62 47.18
Power (multiplicative model) 3(1) 46.61 44.72 45.54 48.39 48.3 48.39
10(2) 69.00 65.25 66.88 67.00 66.26 67.00
30(6) 93.45 91.44 92.28 82.21 80.18 82.21
Moderate LD
Error Rate (no disease) 3(0) 4.86 7.17 4.91 4.54 4.81 4.98
10(0) 4.88 9.8 4.83 4.55 4.92 5.00
30(0) 5.63 11.09 5.03 4.97 5.29 5.56
Power (additive model) 3(1) 44.59 55.8 49.36 49.71 50.51 51.23
10(2) 56.25 72.38 61.36 58.93 59.12 60.72
30(6) 65.47 83.04 71.96 53.29 52.24 55.65
Power (multiplicative model) 3(1) 46.52 57.5 50.98 51.19 52.00 52.65
10(2) 68.42 81.73 72.48 70.66 70.9 72.4
30(6) 93.68 98.04 95.59 86.07 84.34 87.52
Strong LD
Error Rate (no disease) 3(0) 4.96 11.49 5.23 3.88 5.22 5.35
10(0) 5.33 15.68 4.84 3.37 4.88 5.34
30(0) 5.57 17.9 4.89 3.38 4.89 5.64
Power (additive model) 3(1) 45.03 72.29 58.81 53.88 58.2 60.43
10(2) 57.2 89.82 75.74 66.39 71.71 74.3
30(6) 65.56 96.04 86.3 62.84 66.80 72.75
Power (multiplicative model) 3(1) 47.13 74.28 60.88 56.28 60.74 62.77
10(2) 68.45 94.41 84.89 77.14 80.59 83.00
30(6) 93.4 99.92 99.2 91.42 92.24 95.38
Data are given as percentages. Abbreviations are as follows: LE, linkage equilibrium; LD, linkage disequilibrium; and DSL, disease susceptibility loci.However, the assignment of high weights to nonpredis-
posing SNPs can decrease power; bigger differences
between high and low weights leads to greater power
loss. Fortunately, the power loss is generally much less
than the potential power gain that can result from favor-
able weight setting for genes. For example, when the
high:low weight ratio is 3, the randomly assigned weights
result in only 2% power loss for the scenario with one
susceptibility locus among ten independent SNPs in the
gene, whereas a favorable weight assignment would result
in more than a 10% increase in power in the same situa-
tion. However, this pattern does not seem applicable to
the gene with three SNPs in strong LD; in that case, theThe Ameripower loss due to random weighting might be larger
than the power gain when the ratio of high to low weight
is large. Actually, when all SNPs are in strong LD, the effec-
tive number of p values will approach 1, and the higher
weight will be also close to 1 so that the type 1 error can
be controlled. Hence, the favorable weight will only have
a slight effect on the SNPs p values and thus on the power
of the statistic test. Anyway, according to the empirical
simulation, a high:low weight ratio less than 5 seems pref-
erable because the power loss due to the randomweights is
trivial, at least across the scenarios we have tested, whereas
the power gain as a result of corrected weight can be
substantial.can Journal of Human Genetics 88, 283–293, March 11, 2011 287
Table 2. Empirical Power of Alternative Approaches by
Permutation
#SNP (#DSL)
Permuted Fisher
Combination Test
Permuted Original
Simes Test GATES
LE
3(1) 46.47 50.03 48.77
10(1)* 27.18 35.29 33.5
10(2) 55.72 56.68 54.78
30(1)* 16.79 25.89 24.21
30(6) 92.1 83.61 82.55
Moderate LD
3(1) 52.89 55.3 54.18
10(1)* 42.56 42.68 41.02
10(2) 72.56 73.46 72.79
30(1)* 26.36 29.03 27.95
30(6) 95.1 87.21 87.32
Strong LD
3(1) 62.29 62.45 62.77
10(1)* 56.94 53.45 51.18
10(2) 86.02 83.61 83.88
30(1)* 38.78 39.48 38.44
30(6) 99.18 94.56 95.22
Powers are given as percentages. Abbreviations are as follows: LE, linkage
equilibrium; LD, linkage disequilibrium; and DSL, disease susceptibility loci.
An asterisk indicates that only the first locus in each LD block was assumed
as a disease susceptibility locus.Genome-wide Type 1 Error Rates under
Realistic LD Patterns
In the simulation study with real genotypes and permuted
phenotypes from an actual GWAS dataset, GATES does not
show inflation of type 1 error rates across all genes at the
a levels of 0.05, 0.01, 0.001, and 0.0001, regardless of the
number of SNPs in the gene (see Table 3). The use of LD
derived from the current GWAS dataset or from HapMap
CHBdata leads to similar results (Table 3). The Pearson corre-
lationcoefficientbetween the twosetsofgene-basedpvalues
was 0.997. An examination of the QQ plot of the p values of
all genes, genes with three or fewer SNPs, and genes with
more than three SNPs reveals no deviation from a uniform
(0,1) distribution (Figure 3).
Application to Genome-wide Association
Dataset on CD
GATES was implemented in an open-source tool named
Knowledge-Based Mining System for Genome-wide
Genetic Studies (KGG), which was used for analysis of
the SNP-based p values for CD. The program took less
than 2 min to perform a whole-genome scan for the data-
set on an ordinary desktop computer with Intel Core 2
CPU 2.66G Hz, RAM 1.97 GB, and 32-bit Windows XP
Professional Version 2002.288 The American Journal of Human Genetics 88, 283–293, March 1There was an overall inflation of SNP-based p values
(genomic control l 1.1586) in the Meta-analysis dataset
on CD. Barrett et al. (2008)30 argued that, given the large
sample size (3,230 CD cases and 4,829 controls), the over-
all inflation was modest and would not introduce spurious
differences between cases and controls. Nevertheless, we
adjusted the SNP-based p values by the genomic control
inflation factor31 to reduce potential false positives. In
the dataset, 311,638 (49.09%) SNPs were assigned to be
within one ormore of 23,974 genes. The numbers of signif-
icant p values for the SNP-based test, the original Simes
test, and GATES at three levels of family-wise significance
are shown in Table 4. GATES detected more significant
genes than the original Simes test or SNP-based test. At
the family-wise error rate of 0.05, GATES detected five
more significant genes than the SNP-based p values alone.
All significant genes according to SNP-based p values were
also significant by the original Simes test. The extended
Simes test reported two more significant genes, MST1
[MIM 142408] and BSN [MIM 604020], than the original
Simes test; the other genes were significant for both tests.
MST1was convincingly replicated in independent samples
by Barrett et al. (2008).30 Recent studies also support
a contribution from BSN32,33 to CD. At the family-wise
error rate of 0.1, GATES detected five more significant
genes than the SNP-based p values. Among these five
genes, Barrett et al. (2008)30 successfully replicated ITLN1
[MIM 609873], and there is also support for TNFSF15
[MIM 604052] as a candidate gene involved in CD.34–36
In a recent genome-wide meta-analysis of CD in a larger
sample, the susceptibility of the four genes was recon-
firmed.37 The significant genes (FWER % 0.1) and their
SNPs are detailed online in the Table S3.
Using the Gene-Based Test to Guide Replication Studies
After a genome-wide gene-based scan, the next practical
issue is how to use the results to guide follow-up replica-
tion studies. A straightforward strategy is to prioritize
genes on the basis of their p values and then select the
SNPs with the smallest p values within each prioritized
gene for replication. We conceptually validated this idea
by using the released replication results in Table S2 of Bar-
rett et al. (2008)30 for CD. There were 23 SNPs with a signif-
icant replication p value < 3.85E4 (¼ 0.05/130) among
the 130 SNPs in their Table S2. These SNPs could be map-
ped onto 19 known genes. In 13 of these 19 genes, the
same SNP was the most significant SNP within the gene
in both the original Meta-analysis and the independent
replication study (see Table S4 online), suggesting that
choosing the most significant SNP within each selected
gene is usually optimal. However, functional consider-
ations are also potentially relevant for SNP selection. The
most significant SNPs of two genes (IL23R [MIM 607562]
and RTEL1 [MIM 608833]) in the Meta-analysis later
were surpassed in the replication study by other SNPs in
the same gene with greater functional significance. For
IL23R, the most significant SNP in the replication study
is rs11209026, a missense variant. For RTEL1 [MIM1, 2011
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Figure 2. Empirical Type 1 Error and Power of
the Weighted Gene-Based Test
(A) Additive mode and independent SNPs.
(B) Multiplicative mode and independent SNPs.
(C) Additive mode and SNPs in moderate LD.
(D) Multiplicative mode and SNPs in moderate
LD.
(E) Additive mode and SNPs in strong LD.
(F) Multiplicative mode and SNPs in strong LD.
The high weights are assigned to the true suscep-
tibility SNPs (i.e., the favorable weight setting) or
are just randomly assigned to any SNPs within
the gene (i.e., the random weight setting).
Error lines in the (B), (D), and (F) are omitted
because they are identical to those in (A), (C),
and (E), respectively.608833], it is rs2297441, a variant in utr-3. Interestingly,
rs2297441 is also mapped onto a miRNA binding site of
RTEL1 in Sanger’s miRBase.Discussion
The proposed gene-based test, GATES, is a Simes test exten-
sion that is valid for correlated SNPs and capable of incor-
porating previously assigned functional weights of the
SNPs in the gene. The test does not require the raw geno-
type or phenotype data as inputs but requires only the
SNP-based p values and SNP-SNP correlations, and it
need not assume that all SNPs of a gene have the same
direction of effect. It is also very fast because there is no
need for permutation or simulation. GATES can handle
millions of SNPs in less than 10 min, which makes it
convenient for post-GWAS analyses, especially for the
huge datasets that are being generated by genome-wide
meta-analyses38 and imputation,39,40 as well as by next-The American Journal of Hugeneration sequencing technology,41
although it will lack power for rare variants.
We have shown GATES to have correct
type 1 error rates in both simulated and
permuted datasets, regardless of the number
of typed SNPs in the gene or LD structure.
We have also shown that it is similar in
statistical power to alternative gene-based
tests that require permutation or simula-
tion.12,16,42 Furthermore, we have shown
that the power of the test can be improved
by the appropriate assignment of differen-
tial prior weights to the SNPs within a gene.
In the present study, we made a system-
atic comparison between several simple
and efficient methods of combining p
values to guide gene-level association
studies. These tests can be generally catego-
rized into two groups, ones simultaneously
combining all SNPs and others mainly
focusing on the best SNPs. The first groupincludes the logistic regression method, Fisher combina-
tion test (adjusted by permutation), and the VEGAS-Sum
test proposed by Liu et al.16; tests belonging to the second
group are the Simes test, the VEGAS-Max test proposed by
Liu et al. ,16 and GATES in the present study. The first group
of tests are generally more powerful for detecting a gene
withmultiple independent DSL, whereas the second group
of tests can work better when a gene has only one or a few
independent DSL. In addition, the performance of the first
group of tests is more sensitive to the number of neutral
SNPs within a gene. That is, they can be much less power-
ful than the second group of tests for detecting a large gene
withmany typed SNPs but only a few truly associated ones.
Interestingly, the presence of LD invalidates only the
Fisher combination test and tends to increase the statistical
power of the other tests, except for logistic regression,
which has the same power regardless of LD. As a result,
logistic regression is more powerful than other tests
when the SNPs in the gene are uncorrelated but less power-
ful when the SNPs are in LD. Among the second group ofman Genetics 88, 283–293, March 11, 2011 289
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Figure 3. Q-Q Plot of Gene-Based p Values in Real Data under
the Null Hypothesis
The gene-based p values calculated from SNP-based p values for
a real GWAS dataset in which disease status has been randomly as-
signed to individuals; the calculation assumed LD statistics calcu-
lated from the GWAS dataset itself.
Table 4. The Number of Genes Passing the p Value Thresholds
Family-wise
Error Rate SNP p Value Original Simes Test GATESa
0.01 17 (3.21E8) 17 (4.172E7) 19
0.05 22 (1.60E7) 25 (2.09E6) 27
0.1 22 (3.21E7) 30 (4.17E6) 32
a The p value thresholds are identical to those in the left column and are
omitted.
Table 3. Proportion of Rejected Null Hypotheses Given the
Nominal Type 1 Error in a Real GWAS Dataset when the Phenotype
Is Permuted at Random
Nominal Type I Error
0.05 0.01 0.001 0.0001
Actual LD
PG 5.27E2 1.11E2 1.01E3 1.27E4
PG (3 or less SNP) 5.08E2 1.01E2 1.14E3 8.75E5
PG (over 3 SNP) 5.44E2 1.20E2 8.99E4 1.634
HapMap CHB LD
PG 5.29E2 1.12E2 1.01E3 1.27E4
PG (3 or less SNP) 5.06E2 9.97E3 1.14E3 8.75E5
PG (over 3 SNP) 5.51E2 1.23E2 8.99E4 1.634
The proportions are subject to sampling variation.tests, GATES has comparable power but is much faster than
the best-SNP test proposed by Liu et al.16 and can be more
powerful than the original Simes test when the SNPs
within a gene are in strong LD.
GATES could be less powerful than the permutation-
based Fisher combination test and the simulation-based
summation statistic test proposed by Liu et al.16 when it
comes to detecting a gene that is of small or moderate
size but that includes quite a few (say, five or more) inde-
pendent DSL. However, to the best of our knowledge,
this would be a rare scenario in real datasets. Instead, it is
probably more usual for a gene to contain only one or
two independent DSL, in which case the power of GATES
to detect a susceptibility gene is similar to that of the
permutation-based Fisher combination test and the simu-
lation-based summation statistic test proposed by Liu
et al.16 Moreover, the methods based on summation of
SNP-based statistics also have their own weakness, in that
they are less powerful for detecting a large gene with
many typed SNPs that do not have a true effect. Therefore,
when we are uncertain about the true pattern of associa-
tion in a gene, it might be reasonable to adopt GATES
because computation is fast and convenient.
The construction of prior weights is still an open ques-
tion. There is no guarantee that true susceptibility SNPs
will always be assigned high or favorable weighs because
we do not yet have full understanding of the relationship
sequence and function to allow us to accurately predict
the functional consequences of a sequence change. One
potentially useful resource for weight construction is the
Catalog of Published GWAS.43 In comparison to SNPs
randomly selected from genotyping arrays, trait/disease-
associated SNPs (TASs) were significantly overrepresented
only in nonsynonymous sites (odds ratio [OR] ¼ 3.9
(2.2–7.0), p ¼ 3.5E7] and 5 kb promoter regions (OR ¼
2.3 (1.5–3.6), p ¼ 3E7)]; however, they were not overrep-
resented in introns, although 88% of TASs collected
through December 31, 2008 in the Catalog of Published290 The American Journal of Human Genetics 88, 283–293, March 1GWAS were intronic. Nicolae et al. found that TASs were
more likely to be expression quantitative trait loci (eQTL),
and theeQTL informationcanbeused to enhancediscovery
of trait-associated SNPs for complex phenotypes.44 Hence,
it might be possible to construct the prior weights for each
SNP on the basis of the ORs associated with their genomic
annotations. However, many of the GWAS hits are likely
to represent indirect associations, and the sequence at the
associated SNP itself might therefore be of no significance.
Moreover, different classes of diseases (e.g., neurological
diseases and immunological diseases) might have different
distributions of the enrichment across various categories. If
this is true, weights that are specific to a disease, or a disease
class, might be more effective. Unfortunately, the number
of available GWAS hits is still too limited to allow stable
estimates even for a class of diseases, not to mention an
individual disease. As the number of GWAS hits increases,
this obstacle will diminish. Anyhow, as we have shown in
our simulation, the power gain resulting from a favorable
weight setting in GATES is expected to be greater than the
power loss resulting from an arbitrary weight setting, espe-
cially when the ratio of high to lowweight is<5. Therefore,
the use the prior weights to evaluate gene-based association
may be worthwhile when it is feasible to generate reliable
weights.1, 2011
The statistically valid gene-level p values attained with
GATES can facilitate in-depth bioinformatics analysis
because it is usually more appropriate to take the entire
gene (rather than individual SNPs) as a basic analysis
unit. The evaluation of association at the gene level nicely
avoids the difficulties in processing the evidence from
numerous dependent SNPs in biological pathways or
networks. On the basis of these gene-level p values, many
Bioinformatics methods45 originally developed for gene-
set enrichment analysis of microarray expression data
could be readily adopted for the functional analysis of
GWAShits. A commonbasic assumption of the enrichment
analysis is that genes responsible for the same diseases tend
to be distributed within the same biological modules.46
Such an assumption implies that many disease suscepti-
bility genes might not function alone but could be con-
nected to each another in one or more biological modules.
A module can be a protein complex,47 a pathway,48 or
a subnetwork of PPIs.49Within amodule, unknown under-
lying disease-susceptibility genes could be predicted on the
basis of some known ones. The coexistence of multiple
significantly associated genes within the same biological
modules could, in turn, strengthen the evidence of the
involvement of the modules in the development of
disease.50–52 More importantly, the biological modules
could also aid our understanding of the pathogenic mech-
anisms of the disease and therefore suggest novel targets for
drug development. The strategy of integrating multiple bi-
oinformatics resources into genetic analysis is a promising
and important trend for genetic studies in the near future.
An advantage of GATES is that it can use LD information
from a known reference population (e.g., HapMap), and it
therefore canbe used evenwhen individual genotype infor-
mation on the study sample is not available, as long as the
SNP-based p values are accessible. The method behaves
well when the reference population matches closely with
the actual study population. For example, using the LD
information from HapMap Chinese reference sample on
the SNP-based p values of a permuted Chinese dataset
gave the correct type 1 error rate (Table 3), and the gene-
basedpvalues correlatedhighly (r¼ 0.997)with gene-based
p values obtained from an analysis where LD is obtained
from the genotype data of the actual study sample.
However, if the reference population does not match well
with the study population, then the type 1 error rate will
be affected. If the reference population has a generally
higher level of LD than the actual study population, then
the me will be underestimated, and the gene-based test
will tend to be liberal. Conversely, if the reference popula-
tion has a generally lower level of LD than the actual study
population, then the me will be overestimated, and the
gene-based test will tend to be conservative. One problem-
atic scenario is when the SNP-based p values have been ob-
tained from a meta-analysis of multiple populations with
differing LD structures. In practice, apart from African pop-
ulations and population isolates,most outbred populations
such as Europeans and Asians have rather similar levels ofThe AmeriLD, and when the type 1 errors of the gene-based tests for
these populations are calculated from HapMap reference
samples, they are unlikely to be grossly inflated or deflated.
In principle, one can apply this method to combine the
SNP p values of genes within a pathway to produce
a pathway-based p value. However, the complex structure
of pathways might make it more difficult to interpret the
results. A single highly significant SNP p value within
a pathway might lead to a significant pathway p value. If
the gene containing this SNP is only involved in a single
pathway, then this would suggest that this pathway
is important. However, because a gene can belong to
multiple pathways and a large pathway can contain
multiple small pathways, it might be difficult to clearly
identify which pathways are involved in disease etiology.
A gene-based test can obviously only cover SNPs within
and near to genes, and although genes are the most inter-
esting regions of genome, it is certain that some intergenic
SNPs are still of functional significance, for example in
altering the expression of genes at a distance. We suggest
that a gene-based analysis should be complemented by
SNP-based tests of SNPs outside of genes, so that the entire
genome is exhaustively explored for all possible associa-
tion signals. We have implemented this strategy in KGG,
which is a standalone tool with graphic interface. It can
read SNP p values by any statistic tests and LD information
from various sources to perform a gene-based test. In addi-
tion, supported by multiple integrated bioinformatics
databases, KGG can also use the generated gene-based
p values to explore biological pathways and PPI networks.Supplemental Data
Supplemental Data include four tables and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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